Vitamin D in secondary prevention of BPPV
- Conditions
- The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or turning of the head/the body toward the affected ear. The pathophysiology of BPPV is related to a displacement of the otoconia toward the semicircular canals, which may remain floating in the endolymph of the semicircular canal (canalolithiasis) or adhere to the cupula (cupulithiasis).Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2015-003395-72-DE
- Lead Sponsor
- Hospital of the University of Munich
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 219
- Written informed consent to participation in the study
- Age = 18 years
- Patients with BPPV of the posterior, horizontal or anterior semicircular canal (confirmed by diagnostic maneuvers) of different etiologies (idiopathic, traumatic, other vestibular diseases)
- The ability to follow study instructions and likely to attend and complete all visit
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 59
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 160
- Osteoporosis
- Hyper-/Hypocalcemia
- Hyper-/Hypophosphatemia
- Hypercalcuria
- Uro-/Nephrolithiasis in medical history
- Intake of vitamin D-metabolites/-analogues
- Intake of cardiac glycosides
- Sarkoidosis
- Active or intended pregnancy
- Hereditary fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase deficiency, congenital galactose intolerance, congenital lactase deficiency
- Pseudohypoparathyreodism
- Life threatening disease with statistical life expectancy < 12 months
- Former participation in this study or participation in a clinical trial with intake of an investigational drug within the last 30 days before participation in this study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method